Slide 1: Exchange filing cover letter – Investor Presentation
26th October, 2021 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Sc
Slide 2: Investor Presentation Q2FY22
CLICK TO EDIT MASTER TITLE STYLE Investor Presentation Q2FY22 October 26, 2021
Slide 3: Disclaimer
DISCLAIMER CLICK TO EDIT MASTER TITLE STYLE Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact o
Slide 4: Strong traction in core therapies and US momentum drive Q2FY22 performance
Strong traction in core therapies across branded markets and CLICK respiratory continued TO EDIT MASTER TITLE STYLE momentum in the US drive Q2FY22 performance Overall Revenue Overall EBITDA Strong delivery across 10% branded & generic markets; 4% EBITDA Margin Covid contribution (Q2 YoY Growth in I
Slide 5: Strong capital structure and robust free cash flow generation continues in Q2FY22
Strong capital structure and robust free cash flow CLICK TO generation EDIT MASTER continues TITLE STYLE in Q2FY22 Net Cash / Equity Cash Balances2 (INR Cr) 0.12 3,676 3,557 0.10 Mar'21 Sept'21 Mar'21 Sept'21 ▪ Growth in operating profitability and prudent working capital management drives robust fr
Slide 6: Continued expansion in portfolio offerings with long-term partnerships and launches
Continued expansion in portfolio offerings with long-term CLICK TO&EDIT partnerships MASTERacross launches TITLE STYLE our strategic markets ✓ Strategic partnership with Eli Lily for diabetic products Humalog® One India and TrulicityTM ✓ New launches in CNS, Respiratory and ARV therapies to South Af
Slide 7: Financial Performance – Q2FY22
Financial Performance – Q2FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,520 Cr 10% YoY EBITDA INR 1,226 Cr │ 22.2% 4% YoY Q2 FY22 (Consolidated) Revenue1 Break-up Actuals API, 3% Others, 1% vs Q2 FY 21 (Rs Cr) International Total Revenue from Markets, 5,520 10% Operations 15% EBITDA 1,226 4%
Slide 8: One India (Rx + Gx + CHL): Consistent execution driving growth across businesses in India
One India (Rx + Gx+ CHL1): Consistent execution driving CLICK growth TO EDIT across MASTER TITLE businesses STYLE in India Key Business Highlights One India Branded prescription business ❖ Sustained volume traction across therapies in core portfolio Rs. Cr Q2 Y-o-Y ❖ Acute and respiratory nebulizati
Slide 9: Global consumer health franchise gaining traction
Global consumer health franchise gaining traction CLICK TO EDIT MASTER TITLE STYLE 7.0+% contribution to overall revenues in H1FY22; Improving consumer health outcomes Anchor consumer brands in India1 Anchor consumer brands in South Africa 13% #1 #1 41% Pain Relief Category (H1FY22 NRT* (H1FY22 YoY
Slide 10: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global CLICK TO EDIT MASTER TITLE STYLE Access Key Business Highlights SAGA: 8% Y-o-Y South Africa $ Mn ❖ Continued market beating growth in South Africa SA Private (SA) private business; tender business performed in- market Q2 Y-o-Y line with expect
Slide 11: North America: Continued traction in core formulation portfolio
North America: Continued traction in core formulation CLICK TO EDIT MASTER TITLE STYLE portfolio Key Business Highlights North America US Generics ramp-up to multi-quarter high ❖ Steady momentum in core products offsetting price erosion in rest of the $ Mn portfolio Q2 Y-o-Y ❖ New approval: Diflupre
Slide 12: ANDA & NDA Portfolio & Pipeline (As on 30th September)
ANDA & NDA1 Portfolio & Pipeline (As on 30th September CLICK TO EDIT MASTER TITLE STYLE 2021) Total ANDAs 166 18 72 256 & NDAs 18 59 8 4 20 81 8 3 1 9 40 5 Approved Tentatively Under Approval ANDAs/NDAs Approved ANDAs ANDAs/NDAs 2 Cipla Ltd PEFPAR Invagen Partnered ANDAs 1 Does not include Vet produ
Slide 13: International Markets and API
International Markets and API CLICK TO EDIT MASTER TITLE STYLE International Markets API $ Mn $ Mn Q2 Y-o-Y Q2 Y-o-Y 120 14% 111 97 100 80 60 25 -9% 23 40 20 - Q2FY21 Q2FY22 Q2FY21 Q2FY22 Key Business Highlights Key Business Highlights ❖ Emerging markets business resumed middle eastern supplies, dem
Slide 14: Our FY22 priorities include
Our FY22 priorities include CLICK TO EDIT MASTER TITLE STYLE Maintain growth momentum in large branded and unbranded generic franchises of India, South Africa and augment consumer wellness franchise Ensuring Covid portfolio availability and maximize patient reach Expanding lung leadership globally a
Slide 15: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com